Phage Therapy Is Effective against Infection by Mycobacterium ulcerans in a Murine Footpad Model

PLoS Neglected Tropical Diseases

Volumn 7, Issue 4, 2013, Pages

  Trigo, Gabriela ^a,b   Martins, Teresa G ^a,b   Fraga, Alexandra G ^a,b   Longatto Filho, Adhemar ^a,b,c,d   Castro, António G ^a,b   Azeredo, Joana ^b   Pedrosa, Jorge ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d Molecular Oncology Research Center   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIOLYSIS; BURULI ULCER; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; LEG SWELLING; LYMPH NODE; LYMPHOCYTIC INFILTRATION; MOUSE; MYCOBACTERIOPHAGE; MYCOBACTERIUM ULCERANS; NONHUMAN; THERAPY EFFECT;

EID: 84876876365     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002183     Document Type: Article

References (61)

1. Portaels F, Silva MT, Meyers WM, (2009) Buruli ulcer. Clin Dermatol 27: 291-305.
2. Walsh DS, Portaels F, Meyers WM, (2011) Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection. Dermatol Clin 29: 1-8.
3. Hong H, Spencer JB, Porter JL, Leadlay PF, Stinear T, (2005) A novel mycolactone from a clinical isolate of Mycobacterium ulcerans provides evidence for additional toxin heterogeneity as a result of specific changes in the modular polyketide synthase. Chem Bio Chem 6: 643-648.
4. George KM, Pascopella L, Welty DM, Small PL, (2000) A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 68: 877-883.
5. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854-857.
6. Torrado E, Fraga AG, Logarinho E, Martins G, Carmona JA, et al. (2010) IFN-γ-dependent activation of macrophages during experimental infections by Mycobacterium ulcerans is impaired by the toxin mycolactone. J Immunol 184: 947-955.
7. Torrado E, Adusumilli S, Fraga AG, Small PLC, Castro AG, et al. (2007) Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 75: 3979-3988.
8. Marsollier L, Robert R, Aubry J, Saint André JP, Kouakou H, et al. (2002) Aquatic insects as a vector for Mycobacterium ulcerans. Appl Environ Microbiol 68: 4623-4628.
9. Portaels F, Meyers WM, Ablordey A, Castro AG, Chemlal K, et al. (2008) First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis 2: e178.
10. Silva MT, Portaels F, Pedrosa J, (2009) Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis 9: 699-710.
11. World Health Organization (2004) Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). WHO/CDS/CPE/GBUI/2004 pp. 10.
12. Kibadi K, Boelaert M, Fraga AG, Kayinua M, Longatto-Filho A, et al. (2010) Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). PLoS Negl Trop Dis 4: e736.
13. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, et al. (2010) Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375: 664-672.
14. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, et al. (2010) Clinical Efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 54: 3678-3685.
15. Ruf MT, Chauty A, Adeye A, Ardant MF, Koussemou H, (2011) Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLoS Negl Trop Dis 5: e1252.
16. Sopoh GE, Dossou AD, Brun LV, Barogui YT, Houezo JG, et al. (2010) Severe multifocal form of Buruli Ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms. Am J Trop Med Hyg 83: 307-313.
17. O'Brien DP, Robson ME, Callan PP, McDonald AH, (2009) "'Paradoxical'" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust 191: 564-566.
18. Gordon CL, Buntine JA, Hayman JA, Lavender CJ, Fyfe JAM, et al. (2010) All-oral antibiotic treatment for Buruli Ulcer: a report of four patients. PLoS Negl Trop Dis 4: e770.
19. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM, (2011) Phage treatment of human infections. Bacteriophage 1: 66-85.
20. Ahmad SI, (2002) Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. notoriously resistant to antibiotics. Med Hypoth 58: 327-331.
21. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, et al. (2002) Bacteriophage Therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect immun 70(1): 204-210.
22. Capparelli R, Parlato M, Borriello G, Salvatore P, Iannelli D, (2007) Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 51: 2765-2773.
23. Verma V, Harjai K, Chhibber S, (2009) Characterization of a T7-like lytic bacteriophage of Klebsiella pneumoniae B5055: a potential therapeutic agent. Curr Microbiol 59: 274-281.
24. McVay CS, Velásquez M, Fralick JA, (2007) Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51: 1934-1938.
25. Hung CH, Kuo CF, Wang CH, Wu CM, Tsao N, (2011) Experimental Phage Therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrob Agents Chemother 55: 1358-1365.
26. Wills QF, Kerrigan C, Soothill JS, (2005) Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob Agents Chemother 49: 1220-1221.
27. Weber-Dabrowska B, Mulczyk M, Gorski A, (2000) Bacteriophage therapy of bacterial infections: an update of our institute's experience. Arch Immunol Ther Ex 48: 547-551.
28. Jikia D, Chkhaidze N, Imedashvili E, Mgaloblishvili I, Tsitlanadze G, et al. (2005) The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90. Clin Exp Dermatol 30: 23-26.
29. Barrow P, Lovell M, Berchieri Jr A, (1998) Use of Lytic Bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin Diagn Lab Immunol 5: 294-298.
30. Oliveira A, Sereno R, Azeredo J, (2010) In vivo efficiency evaluation of a phage cocktail in controlling severe colibacillosis in confined conditions and experimental poultry houses. Vet Microbiol 146: 303-308.
31. Wright A, Hawkins CH, Anggard EE, Harper DR, (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic resistant Pseudomonas aeruginosa: a preliminary report of efficacy. Clin Otolaryngol 34: 349-357.
32. Mve-Obiang A, Lee RE, Portaels F, Small PLC, (2003) Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun 71: 774-783.
33. Stinear TP, Hong H, Frigui W, Pryor MJ, Brosch R, et al. (2005) Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans. J Bacteriol 187: 1668-1676.
34. Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, et al. (2005) Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun 73: 6299-6310.
35. Sambrook J, Russel DW (2001) Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press.
36. Rybniker J, Kramme S, Small PL, (2006) Host range of 14 mycobacteriophages in Mycobacterium ulcerans and seven other mycobacteria including Mycobacterium tuberculosis-application for identification and susceptibility testing. J Med Microbiol 55: 37-42.
37. Shepard CC, McRae DH, (1968) A method for counting acid-fast bacteria. Int J Lepr Other Mycobact Dis 36: 78-82.
38. Fraga AG, Cruz A, Martins TG, Torrado E, Saraiva M, et al. (2011) Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Infec Immun 79: 421-430.
39. Martins TG, Gama JB, Fraga AG, Saraiva M, Silva MT, et al. (2012) Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection. PLoS One 7: e32740.
40. Fraga AG, Martins TG, Torrado E, Huygen K, Portaels F, et al. (2012) Cellular immunity confers transient protection in experimental Buruli Ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination. PLoS 0ne 7: e33406.
41. Calendar RL, Abedon ST (2006) The Bacteriophages. New York: Oxford University Press.
42. Dabrowska K, Switata-Jelen K, Opolski A, Weber-Dabrowska B, Gorski A, (2005) Bacteriophage penetration in vertebrates. J Appl Microbiol 98: 7-13.
43. Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, et al. (2007) Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun 75: 977-987.
44. Asiedu K, Scherpbier R, Raviglione M, (2000) Buruli Ulcer, Mycobacterium ulcerans infection. World Health Organization WHO/CDS/CPE/GBUI/2000 1: 118.
45. Bruttin A, Brüssow H, (2005) Human Volunteers Receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 49: 2874-2878.
46. McNerney R, Traoré H, (2005) Mycobacteriophage and their application to disease control. J Appl Microbiol 99: 223-233.
47. Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, et al. (1996) Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A 93: 3188-3192.
48. Capparelli R, Ventimiglia I, Roperto S, Fenizia D, Iannelli D, (2006) Selection of an Escherichia coli O157: H7 bacteriophage for persistence in the circulatory system of mice infected experimentally. Clin Microbiol Infect 12: 248-253.
49. McNerney R, Kambashi BS, Kinkese J, Tembwe R, Godfrey-Faussett P, (2004) Development of a bacteriophage phage replication assay for diagnosis of pulmonary tuberculosis. J Clin Microbiol 42: 2115-2120.
50. Rabinovitch A, Aviram I, Zaritsky A, (2003) Bacterial debris - an ecological mechanism for coexistence of bacteria and their viruses. J Theor Biol 224: 377-383.
51. Payne RJH, Phil D, Jansen VAA, Kingdom U, (2000) Phage therapy: The peculiar kinetics of self-replicating pharmaceuticals. Clin Pharmacol Therap pp. 225-230.
52. Tiwari BR, Kim S, Rahman M, Kim J, (2011) Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models. J Microbiol 49: 994-999.
53. Loc Carrillo C, Atterbury RJ, El-Shibiny A, Connerton PL, Dillon E, et al. (2005) Bacteriophage therapy to reduce Campylobacter jejuni colonization of broiler chickens. Appl Environ Microbiol 71: 6554-6563.
54. Sulakvelidze A, Alavidze Z, Morris GJ Jr, (2001) Bacteriophage therapy. Antimicrob Agents Chemother 45: 649-659.
55. Addo P, Owusu E, Adu-Addai B, Quartey M, Abbas M, et al. (2005) Findings from a Buruli ulcer mouse model study. Ghana Med J 39: 86-93.
56. Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, et al. (2005) Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol 7: 1187-1196.
57. Phillips R, Kuijper S, Benjamin N, Wansbrough-Jones M, Wilks M, et al. (2004) In vitro killing of Mycobacterium ulcerans by acidified nitrite. Antimicrob Agents Chemother 48: 3130-3132.
58. Kiszewski AE, Becerril E, Aguilar LD, Kader ITA, Myers W, et al. (2006) The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol 143: 445-451.
59. Prévot G, Bourreau E, Pascalis H, Pradinaud R, Tanghe A, et al. (2004) Differential production of systemic and intralesional Gamma Interferon and Interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun 72: 958-965.
60. Ford ME, Sarkis GJ, Belanger AE, Hendrix RW, Hatfull GF, (1998) Genome structure of mycobacteriophage D29: implications for phage evolution. J Mol Biol 279: 143-164.
61. Fischetti VA, (2010) Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int J Med Microbiol 300: 357-362.